NCT04493138View on ClinicalTrials.gov

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

July 21, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRecurrent Myeloproliferative Neoplasm
Interventions
DRUG

Azacitidine

Given SC or IV

DRUG

Quizartinib

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER